Table 1 Patient, tumor, and treatment characteristics
Characteristic | N = 439 |
|---|---|
Age, years | 67 (55, 74) [25–88] |
Sex | Â |
 Female | 213 (48.5%) |
 Male | 226 (51.5%) |
Prescribed dose/Number of fractions | Â |
 20–24 Gy in 1 fraction | 94 (21.4%) |
 30 Gy in 3 fractions | 72 (16.4%) |
 30–35 Gy in 5 fractions | 249 (56.7%) |
 40–42 Gy in 10 fractions | 10 (2.3%) |
 Others | 14 (3.2%) |
Prescribed dose/Max dose, % | 53.3 (49.8, 69.3) [37.8–95.8] |
Number of metastases | Â |
 1 | 159 (36.2%) |
 2–4 | 143 (32.6%) |
 5–9 | 74 (16.9%) |
 10–19 | 43 (9.8%) |
 20–40 | 20 (4.6%) |
Maximum tumor volume, cc | 0.62 (0.17, 2.50) [0.01–33.25] |
Total tumor volume, cc | 1.07 (0.31, 3.63) [0.01–66.58] |
Primary cancer | Â |
 Lung, non-small cell | 232 (52.8%) |
 Lung, small cell | 61 (13.9%) |
 Breast | 57 (13.0%) |
 Gastrointestinal tract | 37 (8.4%) |
 Kidney | 12 (2.7%) |
 Melanoma | 17 (3.9%) |
 Others | 23 (5.2%) |
Prior history of whole-brain radiotherapy | 31 (7.1%) |
Re-irradiation of lesions previously treated with SRT | 24 (5.5%) |
Presence of neurological signs | 80 (18.2%) |
Use of corticosteroids | 136 (31.0%) |
Receipt of cytotoxic agents | 178 (40.5%) |
Receipt of molecularly targeted agents with anti-VEGF activity | 37 (8.4%) |
Receipt of other molecularly targeted agents | 103 (23.5%) |
Receipt of immune checkpoint inhibitors | 62 (14.1%) |